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Phenotypic heterogeneity in cancers is associated with invasive progression
and drug resistance. This heterogeneity arises in part from the ability of
cancer cells to switch between phenotypic states, but the dynamics of this
cellular plasticity remain poorly understood. Here we apply DNA barcodes
to quantify and track phenotypic plasticity across hundreds of clones in a
population of cancer cells exhibiting epithelial or mesenchymal differen-
tiation phenotypes. We find that the epithelial-to-mesenchymal cell ratio is
highly variable across the different clones in cancer cell populations, but
remains stable for many generations within the progeny of any single
clone—with a heritability of 0.89. To estimate the effects of combination
therapies on phenotypically heterogeneous tumours, we generated quanti-
tative simulations incorporating empirical data from our barcoding
experiments. These analyses indicated that combination therapies which
alternate between epithelial- and mesenchymal-specific treatments even-
tually select for clones with increased phenotypic plasticity. However, this
selection could be minimized by increasing the frequency of alternation
between treatments, identifying designs that may minimize selection for
increased phenotypic plasticity. These findings establish new insights into
phenotypic plasticity in cancer, and suggest design principles for optimizing
the effectiveness of combination therapies for phenotypically heterogeneous
tumours.1. Background
The diversity of cancer cell phenotypes within individual tumours plays a
major role in driving both drug resistance and tumour progression [1,2]. For
decades, the prevailing view has been that phenotypic diversity arises because
tumours are mixtures of cancer cell clones with distinct yet heritable pheno-
types. In this neo-Darwinian model, cancer cell phenotypes are genetically
encoded and thus stably propagated to daughter cells [3–6]. In support of
this model, there are significant genetic differences between different sections
of a tumour, and even across different cells from the same tumours [5–9].
Phenotypic heterogeneity has been documented in breast tumours and
breast cancer cell lines [10,11]. Several recent reports have suggested that
there are bi-directional transitions between cancer cells in distinct phenotypic
states for various kinds of cancers [12–22]. For example, breast cancer cells in
culture transition between mesenchymal (stem-like) and epithelial (differen-
tiated) states [12–14,16,17,23]. Analyses of cells within patient tumours also
suggest that they transition between phenotypic states [18,24]. In any popu-
lation, random transitions of cells between phenotypic states will give rise to
a stable equilibrium in which the different phenotypic states are represented
at fixed proportions [12].
Since phenotypic plasticity has primarily been examined in populations of
cancer cells, it is currently not known if this trait varies across the different
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of phenotype states sorted from tumours and cell lines have
led to conflicting conclusions regarding the contribution of
genetic mutations to phenotypic plasticity [24–27]. While
some studies have confirmed clonal relationships between
states, a key question that remains open is if phenotypic
plasticity can vary across the clones in a single cancer cell
population [28].
Resolving this question—whether the clonal diversity of
cancers influences their phenotypic plasticity—is fundamen-
tal to understanding cancer, and is also important from the
perspective of developing combination cancer therapies. In
particular, optimal combination chemotherapy designs will
depend on whether the clones in a tumour have different
capacities to transition between drug-sensitive and -resistant
states.
Examining this question would require an experimental
approach that can quantify phenotypic plasticity in hundreds
of individual clones within a population of cancer cells. DNA
barcodes combined with high-throughput sequencing have
proven effective for tracking large numbers of clones in
both normal and cancer cell populations [28–30]. Here, we
apply DNA barcodes to quantify the extent to which pheno-
typic plasticity varies across hundreds of clones within a
single population of cancer cells.2. Results
2.1. Labelling of cancer cell clones with DNA barcodes
To track the progeny of single cancer cells, we used retro-
viruses to stably introduce a random DNA sequence (or
barcode) into their genome. These barcodes were introduced
into 1  104 MDA-MB-157 cells at a low multiplicity of infec-
tion (0.13), which we expected would label approximately
1300 individual clones (electronic supplementary material,
figure S1a). After a brief drug selection for the infected
cells, the barcoded clones were expanded in culture over a
span of several months (figure 1). Since the retrovirus pool
contains approximately 2.6  106 random barcodes (elec-
tronic supplementary material, figure S1b), and only
approximately 1300 cells were infected, there was a prob-
ability of 0.31 that more than one cell was independently
infected with the same barcode, and a probability of 6.1 1023
that four or more cells shared a barcode with other cells (elec-
tronic supplementary material, figure S1c). Accordingly, the
number of copies of a given barcode sequence in the genomic
DNA is directly proportional to the size of the corresponding
clone in the population.
High-throughput sequencing of the barcodes from the
pool of clones revealed that the barcodes were well-separated
in DNA sequence space, with an average pair-wise Hamming
distance of 10.5 base pairs. This is consistent with what one
would expect if 1372 DNA sequences of length 14 were
randomly sampled from a space of 300million possible
sequences. Since the barcodes were well-separated in
sequence space, it was straightforward to map reads to bar-
codes even in cases where point mutations arose through
sequencing, consistent with the findings of others [28,31,32];
such reads were an average of 1.7 base pairs from their
parent barcodes.2.2. Clones have heterogeneous phenotypic ratios
We chose to barcode the MDA-MB-157 cell line because this
line contains both epithelial and mesenchymal phenotypic
states that can be robustly separated by fluorescence-
activated cell sorting (FACS). Using an antibody that recog-
nizes keratins 8 and 18, intracellular antigens which mark
luminal epithelial cells in the mammary gland [33], we
were able to separate the cells into keratin 8/18 high or low
fractions (electronic supplementary material, figure S2a,b).
Importantly, this population of cells also contained roughly
equal amounts of the two phenotypic states, with about
40% mesenchymal cells. Having a large minor population
meant we were confident we could accurately detect clones
with small amounts of progeny in the minor state.
To assess the proportion of cellswith epithelial ormesench-
ymal phenotypes within each clone, we separated the
barcoded population into epithelial and mesenchymal frac-
tions with FACS (figure 1). To assess clonal dynamics, the
same population of cells was sampled once weekly for a total
of three time points, each time separating these phenotypes
(figure 2a). After sorting, each population was further divided
into equal halves before extracting and sequencing its DNA.
Using high-throughput sequencing, we quantified the pro-
portion of cells with epithelial and mesenchymal phenotypes
for each of the 1372 barcoded clones in the population.
To estimate the magnitude of the technical error associated
with sample preparation, sequencing and analysis, we com-
pared estimated clone sizes between each of the two
sequenced partitions of these six populations (two sorted popu-
lations at three time points). The clone size estimated for each
barcode was highly reproducible between these technical repli-
cates, with an average Pearson correlation of 0.9119 across the
1372 clones detected (electronic supplementary material,
figure S1d). These observations indicated that this experimental
approach reproducibly quantified the numbers of cells
corresponding to barcoded clones within the population.
Ordering clones by their fraction of epithelial cells
revealed that the majority of clones produced progeny that
were mixtures of cancer cells in the two phenotypic states
(figure 2b, electronic supplementary material, table S1),
with only 11% of clones consisting of only one lineage (stat-
istically indistinguishable from mis-sorted cells). Although
most clones exhibited such phenotypic plasticity, the ratio
of epithelial to mesenchymal phenotypes varied significantly
between clones (Shannon entropy ¼ 3.5).
From the sequencing data we were able to distinguish
three distinct classes of clones: clones with mostly epithelial
cells, clones with mostly mesenchymal cells, and clones that
were a mixture of cells in these two phenotypic states
(figure 2c). The majority of clones (89%) in the population
gave rise to daughter cells in both the mesenchymal and epi-
thelial states, with slightly more than half of the clones (64%)
having a mesenchymal bias. We observed that the distri-
bution of epithelial-to-mesenchymal ratios across clones
was closely approximated by a log-normal distribution
(figure 2d,e), for all three time points. While most clones com-
prised both epithelial and mesenchymal cells, the proportion
of progeny in these two states varied greatly between clones:
93% of clones had a bias significantly different from the bulk
population proportions of the two states.
Although most clones had a mesenchymal bias, epithelial-
biased clones tended to be larger (electronic supplementary
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population of cells being epithelial. Despite this difference,
there was only a weak correlation (0.06) between a clone’s
growth rate and log2 (E/M ) ratio, although we found the
differences in clones’ growth rates to be stable across the time
course (electronic supplementary material, figure S3b–d).2.3. Phenotypic ratios are stably inherited by clonal
progeny
Although phenotypic ratios varied significantly across clones,
they were highly stable for any given clone during the
2 weeks in culture, with an average Pearson correlation of
0.89 (R2 ¼ 0.79, all p, 1 1026) (figure 2f ). Additionally, 81%
of clones’ fraction epithelial differed by less than 0.15 over
2 weeks. This raised the possibility that the epithelial-to-
mesenchymal ratio could be a quantitatively inherited pheno-
type. To quantify the narrow-sense heritability of this trait, we
generated 28 clonal subpopulations from individual cells
expanded in culture over a span of 6 weeks. After expanding
these clonal subpopulations, we used Sanger sequencing to
determine their DNA barcodes. We also used flow cytometry
to determine the phenotypic ratio in each of the cloned sub-
populations, and compared this with the phenotypic ratio of
the same clone in the parental pooled population (figure 3a,
electronic supplementary material, figure S4 and table S2).
Regression analysis of these comparisons indicated that pheno-
typic plasticitywas a highly heritable trait (r ¼ 0.89) (figure 3b).
This heritability was considerably higher than that observedwith
106 datasets with permutated barcode labels that randomized the
relationship between the parental and cloned populations
(figure 3c). This finding indicated that phenotypic plasticities
were stably inheritedeven through the rigorsof single-cell cloning.2.4. Phenotypic plasticity varies across clones in primary
tumours
To assess whether phenotypic plasticity varies across clones in
patient tumours, we analysed data from a recently publishedstudy that performed RNA sequencing on single primary
tumour cells [18]. By identifying clonal relationships between
cells, and determining cell states, we could test whether these
clones also had different cell-state proportions. To identify
clonal relationships, we looked for chromosomal gains and
losses using a sliding average of gene expression moving
across chromosomes, modified from published methods
[18,34]. Although this limited resolution of genetic aberrations
means we are likely to be missing genetic differences between
clustered cells, we are confident the gains and losses of whole
chromosomes reveal distinct clones. This analysis revealed a
common gain in chromosome 7 and loss of chromosome 10
across tumour cells, aberrations commonly found in glioblas-
toma [35], as well as other changes, such as a gain of
chromosome 5 or a loss of chromosome 14 or 13, that were
only present in some cells (figure 4). Hierarchical clustering
grouped single cells into clones based on these inferred chromo-
somal gains and losses, resulting in fourmajor clones (figure 4).
We used the same single-cell RNA sequencing data to
assign cells to cell states, using a published method based
on the mean expression of gene sets defining different
glioblastoma subtypes [18,35], and increased ‘stemness’ [18]
(figure 4). This analysis revealed that while each clone con-
tained cells representing different glioblastoma subtypes, there
were significant differences in subtype scores between clones,
particularly of the mesenchymal subtype (p, 6  1025)
and a stem-like state ( p, 8.0  1024). Although this snap-
shot in time cannot tell us about the stability of these
differences, this result suggests that clones within primary
tumours have different cell-state proportions, consistent
with our previous observations.2.5. Combination chemotherapies enrich for clones
with increased phenotypic plasticity
While there is significant interest in developing combination
therapies that incorporate agents which selectively target
the epithelial and mesenchymal states, the optimal design
of such therapies is likely to depend on the mechanisms
that give rise to phenotypic diversity in tumours. We
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Figure 2. Phenotypic plasticity varies across clones. (a) Cells stably transduced with DNA barcodes were expanded over approximately 1 month into a large popu-
lation. Three times over 2 weeks, samples of the population were sorted by cell state, and each clone’s representation was quantified in these sorted states. (b) The
fraction of each clone in the epithelial state (fraction epithelial) is plotted for each time point, showing the diversity of phenotypic plasticities among clones. Clones
are sorted in ascending order by their fraction epithelial, calculated from the mean clone size in duplicate sorts. (c) Histograms of clones, binned by the fraction of
each clone that is epithelial, show the distribution of clonal plasticity. Each plot is from a different time point. (d ) Histogram of clones binned by their log2 ratio of
epithelial (E) to mesenchymal (M ) cells (log2 (E/M )), with one plot for each time point, showing phenotypic plasticity is approximately log normally distributed
across clones. (e) Quantile/quantile plot with the distribution of log2 (E/M ) across clones plotted against the quantiles of a normal distribution with the same mean
and standard deviation, with one line for each time point. Also plotted is the line y ¼ x (dashed line), representing a perfect normal distribution. ( f ) Each clone’s
log2 (E/M ) in one time point plotted against its log2 (E/M ) in another time point, showing that clones have stable phenotypic plasticity. The R
2 (squared Pearson
correlation coefficient) is shown, and a linear regression of the data is plotted in blue. Each clone’s log2 (E/M ) was calculated from the mean clone size in duplicate
sorted E and M states.
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Figure 3. Phenotypic plasticity is stably inherited. (a) Clonal subpopulations were generated from single cells, and each clone’s phenotypic ratio was evaluated with
flow cytometry. (b) Each single-cell clone’s log2 ratio of epithelial to mesenchymal cells (log2 (E/M )) is plotted against the log2 (E/M ) of the same clone in the
parental pooled population. The Pearson correlation coefficient is shown, estimating the narrow-sense heritability. In black is a linear regression of the data.
Phenotypic ratio is a heritable phenotype. (c) Barcode labels were randomized 106 times, and the Pearson correlation was calculated for each iteration; the observed
correlation (blue circle) was higher than all of the randomizations, suggesting the heritability of phenotypic ratio is not likely due to random chance.
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chemotherapies would affect tumours that are heterogeneous
mixtures of clones with different phenotypic plasticities.
These tumours were simulated to match the plasticities,
sizes and growth rates of the observed clones.
As expected, treatment with an epithelial-specific che-
motherapy enriched for the more-mesenchymal clones,
whereas treatment with a mesenchymal-specific chemotherapy
enriched for themore-epithelial clones; both treatments selected
for clones with reduced phenotypic plasticity. In contrast, a
combination therapy that sequentially applied the epithelial-
and mesenchymal-specific treatments enriched for clones with
increased phenotypic plasticity, with a maximal enrichment
for clones that were equal mixtures of cells in the epithelial
and mesenchymal states (figure 5a). In addition to selecting
for clones with increased plasticity, this combination therapy
was also significantly more effective at reducing tumour
burden relative to eithermonotherapy (11- to 23-fold; figure 5a).
Some of these effects could be magnified by increasing the
number of cycles of combination chemotherapy. As the
number of chemotherapy cycles was increased from one to
three, there was an increase in the enrichment of clones with
higher plasticity (figure 5b). Additionally, we observed
increased tumour sizes with longer simulations, as treatments
typically failed to prevent the outgrowth of few faster-growing
clones. This was reflected in a dramatically increased variation
in the number of surviving cancer cells across simulations.
We found that it was possible to enrich for any given phe-
notypic plasticity by altering the design of the combination
chemotherapy. For example, if seven treatments with an epi-
thelial-specific agent were combined with one treatment
with a mesenchymal-specific agent (instead of the three :
three design considered above), there was a further enrich-
ment of more-mesenchymal clones (figure 5c). Conversely, if
seven treatments with a mesenchymal-specific agent werecombined with one treatment with an epithelial-specific
agent, the most strongly enriched clones were more-epithelial.
Increasing the treatment imbalance only magnified this effect.
However, the most effective combination therapies were
balanced in treatment, and selected for clones with roughly
equal mixtures of epithelial and mesenchymal cell types
(figure 5c). These observations indicated that plasticity
was a clonal phenotype that could be selected for (or against)
by sequentially applying selection pressures for specific
phenotypic states.
We next simulated how combination therapies that sequen-
tially applied epithelial- and mesenchymal-specific treatments
compared with therapies that alternated these treatments,
while leaving unchanged the total dose of each therapy applied.
Although the total dose of therapy applied stayed the same,
a combination therapy that alternated between the mesenchy-
mal- and epithelial-specific treatments was far more effective
(48-fold) at reducing tumour size relative to the sequentially
applied combination, while simultaneously greatly reducing
the selection for clones with increased phenotypic plasticity
(figure 5d). Moreover, we found that doubling the rate at
which the therapies were alternated—while halving their dur-
ations so as to maintain the same total dose of therapy
applied—further reduced tumour size (figure 5d). In contrast
to the repeated sequential therapy design, repeating the alternat-
ingdesignsdidnot result inan increased tumour size, suggesting
that it prevented the enrichment of resistant clones. This obser-
vation demonstrates that the design of combination therapies
has an enormous influence on their effectiveness, even in con-
texts where the total dose of therapy applied remains the same.
3. Discussion
In this study we used DNA barcodes to assess phenotypic
plasticity across hundreds of clones in a single population
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clones give rise to progeny in both the epithelial and
mesenchymal states, and the ratio of epithelial and mesen-
chymal progeny differs between clones. Our results show
that this ratio is stable within a clone, even over the course
of weeks and through the rigors of single-cell cloning.
We speculate that the marked stability of phenotypic
ratios across many generations could be determined by gen-
etic factors, as has been previously proposed [36]. Differences
in many such factors across clones would explain the log-
normal distribution of phenotypic ratios we observed, if
each factor had a small multiplicative effect on phenotypic
ratio. As we found that each phenotypic state is a mixture
of mostly the same clones, despite the bias of clones towards
one state or another, it is not surprising that others rarely saw
genetic differences between populations sorted by phenotype
[24–27].
Phenotypic switching can serve as a bet-hedging strategy
allowing the survival of clones in diverse environments [37].
Phenotypic switching is prevalent across a variety of organ-
isms, including prokaryotes [38,39], yeasts [40,41] and
cancer cells [42]. In these examples, phenotype switching
allows a clone to sample multiple phenotypes with different
sensitivities and resistances, allowing the clone to survive in
changing conditions. Since the epithelial and mesenchymal
phenotypes we studied here are known to correlate stronglywith sensitivity to most cancer therapies [43–45], phenotypic
switching between these states would serve as an effective
bet-hedging strategy for cancer cells. To be sure, cancer cells
are not switching phenotypic states out of an awareness
that this strategy will prove beneficial to them. Rather, as
indicated by our simulations, cancer cell clones that undergo
phenotypic switching have a competitive advantage and thus
undergo a selective expansion when treated sequentially with
therapies that selectively target the mesenchymal and epi-
thelial states. The diversity of phenotypic plasticities
observed across clones allows fluctuating environments to
select for a subset of clones with bet-hedging strategies
optimally suited to a particular environment. Thus, stably
inherited differences in phenotypic plasticity enable tumours
to evolve optimal bet-hedging strategies. Phenotypic switch-
ing is a powerful mechanism for overcoming selection
pressures that vary over time—e.g. chemotherapy regi-
mens—and is consistent with observations of changing
phenotypic proportions in progressing tumours [11].
Supporting this interpretation, the enrichment of a par-
ticular set of clones based on cell state due to drug-induced
selection has been observed in vitro [28]. Resistant clones of
the HCC827 non-small cell lung cancer cell line were
observed to display a more-mesenchymal phenotype than
the parental cell line, suggesting that a heritable difference
in cell state resulted in their expansion during selection.
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observed in a patient’s glioblastoma could arise in the absence
of cellular plasticity if the clones identified by our analyses
consisted of sub-clones with stable and distinct phenotypes.
However, we consider this unlikely since the existence of
cellular plasticity in glioblastomas has been supported by
several single-cell RNA sequencing studies of patient
tumours [18]. While we used gene copy number differences
to distinguish between the various clones, our analyses did
not assess if these copy number distinctions played a func-
tional role in determining clonal phenotypes.
The stable phenotypic plasticity of clones has implications
for the design of combination treatments with phenotype-
selective compounds. As conventional chemotherapeutics
can cause the enrichment of a mesenchymal, resistant popu-
lation [10,43,46], there have been significant efforts to develop
therapies that target the resistant mesenchymal cells [47,48].
Once developed, implementation of an appropriate treatment
regimen will be important for the therapeutic success of these
compounds. Even comparing combination therapies with the
same total doses, our simulations showed the order and sche-
dule of doses have profound effects on the effectiveness of the
therapy. Strikingly, the most simple combination therapy
schedule (one treatment, followed by the other) was also
the worst performing, while more-rapid, repeated alterna-
tions between treatments were far more effective at
reducing tumour burden. While changing selections enriched
for more plastic clones, we found that even more-rapid alter-
nation would reduce clonal enrichment. These simulations
suggest that, without due consideration of treatment sche-
dule, the effectiveness of novel combination therapies could
be undervalued. Additionally, our simulations underscore
the importance of understanding heterogeneity and rec-
ommend alternations to be the most effective combination
therapy.4. Material and methods
4.1. Barcode library construction
Barcodes were synthesized as oligonucleotides from IDT
(Coralville, IA), and are listed in the electronic supplementary
material, table S3 as ClonalBarcode5 and ClonalBarcode3.
The oligonucleotides were annealed and ligated into pBabe
Puro (Addgene #1764, Addgene, Cambridge, MA) that had
been digested with BamHI-HF (New England Biolabs) and
EcoRI-HF (New England Biolabs), treated with calf intestinal
phosphatase (NEB), and purified with a PCR purification kit
(Qiagen). One microlitre of 150 nM annealed clonal barcode
was ligated to 190 ng of digested pBabe Puro using T4
ligase (New England Biolabs) overnight at 168. The ligation
product was purified using 1 volume of AMPureXP
beads (Beckman Coulter) as per the manufacturer’s protocol,
and eluted into 20 ml. Four times, 2 ml of purified ligation
product was transformed into 40 ml of DH5a Electromax
Escherichia coli (Fisher Scientific). Transformed bacteria were
allowed to recover in 1 ml SOC medium, pooled and plated
on LB Agar with 100 mg ml21 Ampicillin in two 245 mm
plates (Corning, Corning, NY). Some transformed mixture
was diluted and plated for counting and colony estimation;
this yielded an estimate of approximately 1.7  106 colonies.
After overnight growth at 378C, colonies were scraped offand plasmid DNA was extracted with a Gigaprep kit
(Qiagen).4.2. Cell culture, virus preparation and infection
MDA-MB-157 cells (ATCC, Manassas, VA) and HEK293T
cells were cultured in DMEM supplemented with 10% fetal
bovine serum, Penicillin and Streptomycin and GlutaMax
(Thermo Fisher Scientific). Viral barcoding vectors were
transfected into subconfluent HEK293T cells with pCL-
10A1 retroviral packaging plasmid using Fugene 6 (Promega,
Madison, WI) and viral supernatant was collected and
concentrated with polyethylene glycol (PEG). For concen-
tration, viral supernatant was spun at 931 gravities for
4 min and decanted into 1/5.5 volumes of sterile 50%
PEG-3350 in phosphate-buffered saline (PBS). After an over-
night 48 incubation, the mixture was spun for 1455 gravities
for 20 min, decanted, spun again at 524 gravities for 4 min,
and the pellet resuspended in PBS with 1% bovine serum
albumin and frozen at 2808C. For infection, 1  104 cells
were incubated with concentrated virus and 30 mg ml21 pro-
tamine sulphate and spun at 1455 gravities for 1.5 h. Viral
concentration was optimized to infect approximately 10% of
cells. After 48 h, cells were selected with 3 mg ml21 puromy-
cin to kill uninfected cells. Barcoded cells were expanded
without discarding cells until the population was at least
2  107 cells, and subsequently split into subpopulations no
smaller than 2  106 cells to maintain clonal representation.4.3. Amplification and sequencing of barcode plasmid
pool
Barcodes were amplified using PCR from 2 ng of plasmid
with 20 cycles of amplification, using ClBc_5_primer_AAG
and ClBc_3_primer_CCT (see electronic supplementary
material, table S3). PCR products were run on a 2% agarose
gel, extracted using a gel extraction kit (Qiagen), and
sequenced on a HiSeq 2000 (Illumina), TruSeq-DNA
adaptors. The sequencing primer used was ClBc_seq_primer
(see electronic supplementary material, table S3). Sequence
data were analysed with a custom Python script that first
filtered by quality, where reads were only accepted if they
contained fewer than 14 base pairs with a quality score
,25, and had no base pairs with a quality score ,10.
Additionally, reads were only accepted if they contained
the index sequences marking each library and the sequences
common to every barcode, and every base in those sequences
had a quality score of .25. This resulted in 2.4  106 reads.4.4. Estimation of plasmid pool complexity
Pool complexity was estimated based on published methods
of estimating the number of classes based on sample coverage
[49]. Where N equals the estimated number of barcodes, n ¼
the sample size (2 447 204 reads), D ¼ the number of unique
barcodes observed (1 530 822), and f1 ¼ the number of bar-
codes observed only once (989 844), the sum of the
probabilities of observed classes of barcodes was estimated
as C^ ¼ 1 f1=n ¼ 0:5955. This was used to estimate a lower
bound on the number of unique barcodes in the plasmid
pool, as N ¼ D=C^ ¼ 2 570 562.
rsob.royalsocietypublishing.org
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sequences of complexity N were randomly sampled (with
replacement) n times, and the count of each unique sequence
in the sample determined.
4.5. Poisson modelling of viral infection
Viral infection of cells was modelled based on the multiplicity
of infection and assuming that the number of infections per
cell followed a Poisson distribution, as has been observed
by others [50,51]. Multiplicity of infection (MOI) was esti-
mated from the estimated number of cells infected (1.3 
103 out of 1  104); where m ¼MOI and P(n) ¼ the pro-
portion of cells infected with n viruses, the MOI was
estimated from Pðn . 0Þ ¼ 1 em [50]. The MOI was there-
fore estimated as 0.139. A Poisson PDF was calculated from
using this MOI as the m parameter, and was used to estimate
the number of cells infected with different numbers of
barcodes.
4.6. Probability calculations of all cells uniquely
barcoded, and simulations of barcodes in multiple
cells
The probability at least two cells share a barcode after infec-
tion, or P(A), was calculated as 12 P(A0), where P(A0) is the
probability that all cells have unique barcodes. This calcu-
lation is analogous to the so-called ‘Birthday Problem’ [52].
Where N ¼ the estimated number of barcodes (from sequen-
cing the barcode plasmid pool, 2 570 562) and c ¼ the number
of cells infected (1372),
PðA0Þ ¼
Yc1
i¼1
N  i
N
:
To estimate the probability of different numbers of cells
sharing barcodes with other cells, c barcodes were randomly
sampled from N barcodes, 5  105 times with replacement.
4.7. Intracellular flow cytometry
Cells were trypsinized, washed in DMEM supplemented
with 10% fetal bovine serum (Sigma-Aldrich, St. Louis,
MO), washed 2 in PBS, and spun (as with all subsequent
washes) at 524 gravities for 3 min. The pellet was disrupted
by vortexing and the cells fixed by dripping in 2 ml of ice-
cold 70% ethanol while vortexing. Vortexing was continued
for 30 s and the cells incubated overnight at 48C. Cells were
blocked by washing 3 in FACS buffer (FB), consisting of
PBS supplemented with 6% fetal bovine serum (Sigma-
Aldrich). Cells were filtered through a 40 mm filter, counted
on a haemocytometer, resuspended to 1  106 cells ml21 in
FB and stained with a 1 : 50 dilution of mouse anti K8/18,
clone C51 (Cell Signaling, Danvers, MA), for 1–2 h on ice.
After washing 3 with FB, cells were stained in FB at a con-
centration of 1  106 cells ml21 and a 1 : 1000 dilution of goat
anti mouse Fab Alexa Fluor 488 (Cell Signaling), incubating
for 0.5 to 1 h on ice in the dark. Cells were washed 3 in
FB and resuspended at 1  106 cells ml21 in FB. Samples
were run on a Fortessa (Becton Dickinson, Franklin Lakes,
NJ), and flow cytometry data were analysed with FLOWJO
(Tree Star, Ashland, OR).4.8. Fluorescence-activated cell sorting
For single-cell cloning, clonally barcoded MDA-MB-157 cells
were trypsinized, washed with PBS supplemented with 3%
FBS, sent through a 40 mm filter, and resuspended to 1 
106 cells ml21. A FACSaria (Becton Dickinson) was used to
sort single cells into wells of 96-well plates, each well contain-
ing 100 ml of DMEM with 10% FBS.
After expansion of the barcoded population of cells, a
portion of the cells were stained for keratin 8/18 expression
and sorted via FACS. Portions were separated out of the
population and sorted at three time points each separated
by a week (day 0, day 7, day 14).
For these sorts based on keratin 8/18 expression, cells
were stained as in intracellular flow cytometry, but stained
at 1  107 cells ml21 in FB and with a 1 : 60 dilution of
mouse anti K8/18, clone C51 (Cell Signaling), for 1–2 h on
ice. After secondary staining and washes, cells were resus-
pended at 1  107 cells ml21 in FB and sorted on a
FACSAria (Becton Dickinson) set to maximize yield. Sorted
samples were analysed on the FACSAria to measure the
proportion of cells mis-segregated, counted on a haemocyt-
ometer, and split in half. Barcodes were extracted from
these cells as described below.4.9. Extraction and amplification of barcodes
from genomic DNA
Genomic DNA was collected with a DNeasy kit (Qiagen,
Venlo, The Netherlands). All genomic DNA was digested
with BamHI and EcoRI (New England Biolabs, Ipswich,
MA), using 3 units mg21 and digesting for 1 h at 378. Digested
DNAwas directly purified from solution with a gel extraction
kit (Qiagen), and barcodes size-selected with Agencourt
AMPure XP beads (Beckman Coulter, Brea, CA). For size
selection, one-half volume of beads was added to the DNA
mixture to bind to large DNA fragments, mixed by vortexing,
and incubated at room temperature for 5 min. After precipi-
tating the beads with a magnet, the supernatant containing
small DNA was removed, and DNA was purified from the
supernatant with a gel extraction kit (Qiagen) and quantified
on a Nanodrop (Thermo Scientific). Barcodes were amplified
from purified size-selected DNA using 25 cycles of PCR with
ExTaq (Takara Bio, Kyoto, Japan), assembling the reaction
mixture on ice. Template was added to a final concentration
of 10 ng ml21, and all size-selected DNA was used as tem-
plate. This PCR step was used to also add library-specific
index sequences (to allow for sequencing multiple samples
in the same sequencing lane) and adaptor sequences for
high-throughput sequencing. Index sequences were designed
to have at least two differences from all other index
sequences. Primer sequences are listed in the electronic sup-
plementary material, table S3. PCR products were purified
with a PCR purification kit (Qiagen). Samples of 4, 2 and
1 ml of each PCR product were run on a 2% agarose gel
and the intensity of the 131 base pair band quantified electro-
nically. Samples’ relative DNA concentration was computed
with linear regression and the samples were combined in
equimolar ratios. This combined library was run on a 2%
agarose gel, and the 131 base pair band was purified with
a gel extraction kit (Qiagen). The purified band was
sequenced on a HiSeq2000 (Illumina, San Diego, CA); the
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Sequencing data were analysed with custom Python scripts.
Reads were first filtered by quality, where reads were only
accepted if they contained fewer than 6 base pairs with a
quality score, 25, and had no base pairs with a quality
score , 15. Additionally, reads were only accepted if they
contained the index sequences marking each library and the
sequences common to every barcode. These steps reduced
1.67  108 reads to 1.01  108 reads. This quality filtering pro-
cedure was more stringent than that used to analyse barcodes
from the plasmid pool due to the increased cycles of amplifi-
cation involved in library construction and lower starting
pool complexity, which resulted in lower quality reads.
Reads were then separated based on library-specific
sequences that were introduced during PCR to distinguish
samples. Taking reads for barcodes seen at least twice, we,
as others, combined reads that could be connected with few
mismatches, using the most abundant barcode to represent
the group and giving it the abundance of the sum of the
group’s reads [29,53]. To avoid erroneously combining
barcodes that were by chance similar in sequence, we
repeatedly iterated down the list of barcodes ordered by
abundance, grouping together less abundant barcodes that
were within one mismatch, and then repeating the process
grouping together less abundant barcodes within two, three
and four mismatches. We then removed from analysis any
barcodes that were not detected in any libraries from one or
more time points.
These data were used to test for clones’ bi-lineage poten-
tial and cell-state bias, below, to allow for statistical analysis
of clones based on the actual number of reads.
For further analysis, reads for each library were normal-
ized by dividing by the sum of reads for that library
multiplied by the fraction of the population consisting of
that cell state at the time of sorting, being 60% for K8/18
high and 40% for K8/18 low. Any barcodes not found in a
library were given a fractional value of 1  1026 for that
library. To deal with sort contamination, for each barcode,
and for each time point, we subtracted from each sorted
library the average fraction of total reads of the other sorted
populations multiplied by the fractional contamination
observed in that sort from post-sort flow cytometry. Any bar-
code abundance thus brought to less than zero was given a
value of 1  1026. After determining in this way the size of
each clone in each state, the results from the two sequenced
replicates from each time point (see above) were combined
by taking their mean.4.11. Testing for clones’ bi-lineage potential
To determine whether clones did in fact have bi-lineage
potential, we asked whether, for each clone, we could reject
the hypothesis that there were as many reads as could be
expected via sort contamination (mis-sorted cells), assuming
each clone was composed entirely of cells in one state.
The proportion of mis-sorted cells was determined via flow
cytometry of the sorted cells (see above), here represented
as sm,t for the proportion of mesenchymal-sorted cells attime t that were actually mis-sorted epithelial cells, and simi-
larly se,t.
After sorting at three time points (days 0, 7 and 14; see
above), each pool of sorted cells was split into two, and
sequenced (see above). At each time point, the reads for
each clone in each state were summed, creating re(c, t) for
the summed epithelial (keratin 8/18þ) reads of clone c at
time point t, and similarly rm(c, t). As the count of observed
reads for each clone was being compared with reads expected
from sort contamination, the un-normalized reads from
clones were used (see above).
In order to test for bi-lineage potential, we calculated for
each state, at each time point, the expected probability of a
read in the other state from sort contamination, assuming
all cells were in the first state, or pCe (t) for the probability
of epithelial reads being mis-called as mesenchymal, assum-
ing all cells were epithelial, and pCm (t) for the probability of
mesenchymal reads being mis-called as epithelial, assuming
all cells were mesenchymal.
For ease of understanding the calculation of these prob-
abilities, the reads from the epithelial-sorted population can
be visualized as a combination of reads from real epithelial
cells (totalling (12 se) times the sum of epithelial-sorted
reads) and reads from real mesenchymal cells (totalling se
times the sum of epithelial-sorted reads). Similarly, the
reads from the mesenchymal-sorted population can be
viewed as a combination of reads from real mesenchymal
cells (totalling (12 sm) times the sum of mesenchymal-sorted
reads) and reads from real epithelial cells (totalling sm times
the sum of mesenchymal-sorted reads).
Therefore, the sum of reads from correctly sorted epi-
thelial cells (E) at time t is
E ¼ ð1 se,tÞ 
X
k[clones
reðk, tÞ:
The sum of reads from incorrectly sorted epithelial cells
(E0) at time t therefore is
E0 ¼ sm,t 
X
k[clones
rmðk, tÞ:
The sum of reads from correctly- and incorrectly-sorted
mesenchymal cells was calculated similarly.
pCe is defined as the proportion of all epithelial
reads that were mis-called as mesenchymal, which is
equal to E0/(E þ E0). Therefore, these probabilities were
calculated as
pCeðtÞ¼ sm,t
P
k[clones rmðk,tÞ
sm,t
P
k[clones rmðk,tÞþð1se,tÞ
P
k[clones reðk,tÞ
,
and
pCmðtÞ¼ se,t
P
k[clones reðk,tÞ
se,t
P
k[clones reðk,tÞþð1sm,tÞ
P
k[clones rmðk,tÞ
:
For each time point, and each clone, these probabilities
were used to test the hypothesis that each clone was actually
monolineage. To test the null hypothesis that all clones were
epithelial, each clone was evaluated at 12 the CDF of a bino-
mial distribution with p ¼ pCe and n ¼ reðc, tÞ þ rmðc, tÞ for
clone c, evaluated at x ¼ rm(c,t). Similarly, to test the null
hypothesis that all clones were mesenchymal, each clone
was evaluated at 12 the CDF of a binomial distribution
with p ¼ pCm and n ¼ reðc, tÞ þ rmðc, tÞ for clone c, evaluated
at x ¼ re(c,t). These resulting p values from all states and all
rsob.royalsocietypublishing.or
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using the Benjamini–Hochberg method [54]. The null
hypothesis that a clone was monolineage at a particular
time point was rejected to control the false discovery
rate (FDR) at 0.05. A clone was declared monolineage if
the null hypothesis was rejected at all time points for the
same state, and at no time points for the other state. A
clone was declared bi-lineage if the null hypothesis was
rejected in both states (still at the FDR of 0.05) in at least
one time point.g
Open
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To test whether clones had bias in cell state, we attempted
to reject the null hypothesis that each clone’s cell-state
proportions matched the population cell-state proportion.
Again, pre-normalized reads (see above) were used. Reads
from the two sequenced replicates of each sorted popu-
lation were summed. For each clone, at each time point,
the expected number of reads in the epithelial and
mesenchymal states were calculated, or Ee(c, t) and
Em(c,t), respectively:
Eeðc, tÞ ¼ ðreðc, tÞ þ rmðc, tÞÞ  rt,
Emðc, tÞ ¼ ðreðc, tÞ þ rmðc, tÞÞ  ð1 rtÞ
and rt ¼
P
k[clones reðk, tÞP
k[clones reðk, tÞ þ rmðk, tÞ
:
The x2 test was used to examine the significance of the
fit between the observed and expected reads. The upper
CDF of the x2 distribution with one degree of freedom was
evaluated at x, where:
x ¼ ðreðc,tÞ  Eeðc,tÞÞ
2
Eeðc,tÞ þ
ðrmðc,tÞ  Emðc,tÞÞ2
Emðc,tÞ :
These resulting p values from all time points were
corrected for multiple hypothesis testing using the
Benjamini–Hochberg method [54]. The null hypothesis that
a clone at a time point had a cell-state bias matching the
population cell-state proportions was rejected so as to control
the false discovery rate at 0.05. Clones were declared signifi-
cantly different from the population cell-state proportion if
this null hypothesis was rejected at all time points.4.13. Fraction epithelial and log2 (epithelial/
mesenchymal) ratio calculations
After normalizing the sequencing data of sorted cells (see
above) to determine the size of each clone in the epithelial
and mesenchymal states, and after subtracting those reads
estimated to come from sort contamination, each clone’s
cell-state bias was determined, represented by the fraction
of the clone that was epithelial (fraction epithelial) or the
log2(epithelial/mesenchymal) ratio (log2 (E/M )).
Here, Ec,t equals the normalized fraction of cells of clone c
in the epithelial state at time point t, and similarlyMc,t. These
estimated cell counts are normalized such that the sum of epi-
thelial and mesenchymal counts across clones at each time
point equals one. For both of these calculations, dividing E
by M or (E þM ) cancels out this normalization factor,
rendering the calculations equivalent to those using counts
of cells. The fraction of clone c epithelial at time point t wascalculated as
Ec,t
Ec,t þMc,t :
The log2 (E/M) ratio for clone c at time point t was
calculated as
log2
Ec,t
Mc,t
:
The log2(E/M) ratio for clone c averaging across the three time
points was calculated as
1
3

X3
t¼1
log2
Ec,t
Mc,t
:4.14. Testing the significance of the correlation of
clones’ cell-state bias across time points
The Pearson correlation of clones’ log2(E/M) ratio across
time points was determined to assess the stability of cell-
state bias. To determine the probability of randomly obtain-
ing a correlation higher than the one observed in each of
the three comparisons across time points, the barcode labels
of one time point in each comparison were randomly
shuffled. After each randomization, the Pearson correlation
was evaluated and the correlation coefficient r recorded.
After 1  106 such randomizations, the distribution of
randomized r values was compared with the observed r,
and the proportion of randomized r greater than observed
r determined.4.15. Clone growth rate calculations
From the frequency of splitting during cell culture, the
population of cells was estimated to double approximately
three times per week. The population of cells sorted at the
first time point consisted of 2.9  107 cells, and this popu-
lation growth rate was used to estimate the number of
cells at 1 and 2 weeks later, at the second and third time
points. As the barcode sequencing information was used to
calculate relative size of each clone as a fraction of the
total population, these population cell numbers were used
to compute the cell numbers of each clone at each time
point through multiplication. Each clone’s number of cells
at the second and third time points (Ni,c) were compared
with cell numbers from the first time point (N0,c) to compute
each clone’s growth rate over these two intervals; the
two rates were averaged to compute each clone’s growth
rate (kc):
kc ¼ 12
X2
i¼1
ln
Ni,c
N0,c
 
 1
7i
:4.16. Calculation of Shannon entropy of the distribution
of clones’ epithelial/mesenchymal ratio
After calculating the geometric-average log2 (epithelial/
mesenchymal) for each clone across the three examined
time points, clones were binned from the minimum ratio to
the maximum ratio in bins of width 1 (corresponding to a
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thus binned was calculated.
4.17. Flow cytometry of single-cell clones
Single-cell clones were trypsinized, washed in DMEM sup-
plemented with 10% fetal bovine serum (Sigma-Aldrich),
and washed 2 in PBS. Cells were fixed as in intracellular
flow cytometry. To serve as an internal staining control for
the single-cell clones, pooled clones (the parental barcoded
population) were fixed in the same way as the single-cell
clones. This pooled clone population was resuspended at
1  106 cells ml21 in PBS and covalently stained with
1 ml ml21 of Blue Live/Dead Discrimination Dye (Thermo
Fisher Scientific, Cambridge, MA) for 30 min on ice in the
dark. Cells were blocked by washing 3 in FACS buffer, fil-
tered through a 40 mm filter, counted on a haemocytometer,
and resuspended to 1  106 cells ml21 in FB. For analysis of
single-cell clones, clones were mixed 1 : 1 with samples
from the covalently stained pooled clones. Samples were
then stained as in the intracellular flow cytometry protocol
and run on a Fortessa (Becton Dickinson), and the flow cyto-
metry data analysed with FLOWJO. After using FLOWJO gating
to remove debris, the flow cytometry data were exported
and analysed with a custom Python script. In brief, this
script separated the cells of the pooled clones, and determined
thresholds of K8/18 staining to gate E and M from this popu-
lation such that the gates contained the same proportion of
cells as the gates used for cell sorting. These gates were then
used to determine the proportion of cells from the single-
cell clone that would have been sorted as epithelial or
mesenchymal to calculate the log2 (epithelial/mesenchymal).
4.18. PCR and Sanger sequencing of barcodes from
single-cell clones
Genomic DNAwas collected with a DNeasy blood and tissue
kit (Qiagen) as per the manufacturer’s instructions. Barcodes
were amplified with nested PCR, using two sets of primers
(IDT, Coralville, IA) (first ClBc_A5 and ClBc_A3, then
ClBc_B5 and ClBc_B3; see electronic supplementary material,
table S3) to specifically amplify one band. The initial genomic
DNA concentration was 1.2 ng ml21, and each round of PCR
was 25 cycles. The PCR product was purified with a PCR
purification kit (Qiagen) and sequenced with Sanger
sequencing (Genewiz, South Plainfield, NJ).
4.19. Analysis of correlation of single-cell clone/pool
phenotypic ratio
Narrow-sense heritability was calculated as the Pearson cor-
relation coefficient [55]. Twenty-eight clones were deemed
sufficient as power analysis showed a power of 0.96 to
reject the null hypothesis at a significance of 0.01 for corre-
lations of 0.7, calculated using the pwr package in R. To
determine the probability of randomly obtaining a correlation
higher than the one observed between single-cell clones’ phe-
notypic proportion and those clones’ phenotypic proportion
in the pooled experiment, the barcode labels of single-cell
clones were randomly shuffled between the single-cell
clones using a custom script. After each randomization the
Pearson correlation was evaluated and the correlationcoefficient r recorded. After 1  106 such randomizations,
we compared the distribution of randomized r values with
the observed r.4.20. Glioblastoma single-cell RNA sequencing data
Normalized single-cell RNA sequencing data from primary
glioblastoma tumours were obtained from the Gene
Expression Omnibus (accession GSE57872) [18].4.21. Copy-number estimation from single-cell RNA
sequencing data and clone separation
As has been previously described [18,34], changes in copy
number were estimated through analysis of single-cell RNA
expression by chromosomal location. Mean normalized (by
gene across cells) log2(TPM þ 1) RNA values from single
cells were accessed from GSE57872 [18,56]. RNA data were
from cells that were identified either as non-cancer cells or
as cells from tumour MGH31. For the purposes of determin-
ing copy-number variation, these data were thresholded, so
that values greater than were set to 3, and values less than
23 were set to 23. For each cell, we computed a sliding aver-
age of the expression of 101 genes moving down the list of
genes with RNA data ordered by chromosomal location, to
build a copy-number variation profile (CNV profile). We
then centred each cell’s CNV profile at 0 (subtracting from
each profile the mean value) to deal with any differences in
expression remaining across cells. This meant that the CNV
profile value for cell j at position i (CNVi,j) is
CNVi,j ¼
CNV0 i,jP
c[cells CNV i,c
,
where
CNV0 i,j ¼ 1101
Xk¼iþ50
k¼i50
RNAk,j;
RNAk,j ¼
log2ðTPMk,j þ 1ÞP
c[cells log2ðTPMk,c þ 1Þ
 1jcellsj :
To normalize to the average expression by chromosomal
location, so as to deal with differences in expression across
chromosomes, each cell’s CNV profile was normalized
using an averaged CNV profile from normal cells (CNVBase),
computed for each genomic location through an identical
sliding-average strategy from normal neural cells identified
in the same RNA-seq dataset [18]. For each cell, this
normalized CNV (CNVnorm) was calculated as follows:
CNVnorm i,j¼
CNVi,jCNVBase i, if CNVi,j.CNVBase iþ0:3
CNVi,jCNVBase i, if CNVi,j,CNVBase i0:3
0, ifCNVBase i0:3,CNVi,j,CNVBase iþ0:3
8<
:
In this way, CNV values were only recorded if they
deviated significantly from the value obtained from normal
cells, where a difference of 0.3 corresponds to a 23% change.
The cells’ normalized CNV profiles were clustered via
Ward’s method, using the Euclidean distances between
CNV profiles. This method clusters vectors by finding, at
each step, the pair of clusters that leads to the minimum
increase in within-cluster variability when the clusters are
combined. In this way, the hierarchical clustering of CNV
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cell RNA sequencing data
Cells were classified by subtype as previously described [18].
Cells were scored by subtype using published lists of genes
enriched in each subtype [35], or marking cells with increased
stemness [18]. Mean normalized (by gene, across cells) log2
(TPM þ 1) RNA values for single cells were accessed from
GSE57872 [18,56]. For each cell, a score was calculated for
each subtype. These scores for cell i for subtype j (Si,j) were
calculated by taking the average expression of classifier
genes for subtype j (Gc) in cell i, and subtracting the mean
expression of every gene in cell i:
Si,j ¼
X
g[Gc
RNAg,i  1jGj 
X
g[G
RNAg,i,
where RNAg,i ¼
log2ðTPMg,i þ 1ÞP
c[cells log2ðTPMg,c þ 1Þ
 1jcellsj :
To evaluate each individual score for significance, we
adapted a previously published method [18], evaluating the
enrichment of each score relative to random sets. For each
subtype, we made 100 random subtype-classifier gene sets
from randomly sampling the set of sequenced genes. Each
random set had the same number of genes as the real subtype
gene set. We called each cell’s subtype score as enriched or
depleted by comparing it to these random scores. If the real
score was greater than 95% of the random scores, we called
it enriched, whereas if the real score was less than 95% of
the random scores, we called it depleted.
To determine whether clones had different distributions
of subtype scores, suggesting differences in plasticity, we
evaluated the distributions of subtype scores across cells
grouped into clones by the clustering above with a
Kruskal–Wallis test.4.23. Simulations
Mechanistically, a ‘tumour’ was seeded with 500 clones. Each
clone was assigned a fraction epithelial, growth rate and cell
numbers matching a randomly chosen observed clone, so as
to simulate the distribution of the observed growth rates and
fraction epithelial. Both the growth rate and fraction epithelial
parameters were inherent to the clone for the entirety of the
simulation. Each clone’s starting cell numbers were drawn
from those observed at day 0 of sorting (see above). After
instantiation of the tumour, growth was modelled under
different treatment regimes, with 15 time points modelling
a day. The amount of cells for each clone after division
were calculated as: N0s,iðtÞ ¼ Ns,iðt 1Þ  21=Di , where Ns,i(t)
represents the number of cells of clone i in state s at time t,
Di represents the doubling time (in the time scale of the simu-
lation, where 15 time points is equivalent to 1 day) of clone i.
At each time point, cells were also allowed to differen-
tiate. Each clone’s transition probabilities for going from
epithelial to mesenchymal or mesenchymal to epithelial
were defined so that 20% of cells changed state per division,
and the ratio of transition probabilities matched the clone’s
defined equilibrium of cell states; in this way, the cloneshave stable cell-state proportions at equilibrium and slowly
return to equilibrium after the cell-state ratios are perturbed
through selection. This probability of differentiation was
chosen to reflect those observed in other contexts [12]. The
resulting number of cells of clone i in state s (where the
other state is s’), or N1s,i, as a consequence of differentiation
is as follows:
N1s,iðtÞ ¼ N0s,iðtÞ þN0s0 ,iðtÞ 
Ps0 ,i
Di
N0s,iðtÞ 
Ps,i
Di
:
Here, Ps,i represents the probability that a cell of clone i
differentiates from state s to state s’. This was calculated as
follows, where Ri represents the equilibrium epithelial :
mesenchymal ratio of clone i: PM,i ¼ Ri  c=ð1þ RiÞ and
PE,i ¼ c=ð1þ RiÞ; c here represents the probability of a cell
differentiating during a division, or 0.2 as discussed above.
If no treatment is simulated during this time point, N1s,i is
now the final count of cells for clone i in state s for time
point t, or Ns,i(t).
Treatments were applied as mesenchymal-specific or
epithelial-specific, where a mesenchymal targeting therapy
killed a 10-fold higher fraction of the mesenchymal cells com-
pared to epithelial cells. This was chosen to match the relative
effectiveness of certain in vitro compounds on cells in differ-
ent differentiation states [57]. The number of cells remaining
after death (C2s,i) for a treatment targeting state s is calculated
as N2s,iðtÞ ¼ N1s,iðtÞ  ð1 dssÞ, and for a treatment targeting
state s’ (the other state), N2s,iðtÞ ¼ N1s,iðtÞ  ð1 ds
0
s Þ, where
ds
0
s ¼ 0:01 ¼ 0:1 dss. In this case N2s,i is now the final count
of cells for clone i in state s for time point t, or Ns,i(t).
Each treatment cycle killed a fraction of the cells for
30 time points, simulating a course of therapy for 2 days,
which was followed with 20 time points of no treatment.
The simulation was ended after the conclusion of treat-
ment-rest periods; the number and pattern of treatment-rest
periods varied among the simulations. A variety of treatment
combinations were simulated as detailed in the results.
To compare the results of different simulations, clones were
binned by their fraction epithelial. Each clone’s fold change
in cell numbers during the simulation ( fci for clone i) was
computed as
fci ¼ Ni,sðtendÞ þNi,s
0 ðtendÞ
Ni,sðt0Þ þNi,s0 ðt0Þ ,
where Ns,i(t) represents the number of cells of clone i in state
s at time t, t0 is the time point of the start of simulated
treatments, and tend the time point of the end of simulated
treatments. For each bin of clones by fraction epithelial, the
median fold change in cell numbers for the clones in each
bin was computed. The sum of cells across clones at the
last point was also computed for each simulated treatment.
Simulations were repeated 500 times, and the 0.1, 0.5 and
0.9 quantiles of the median clone fold change for each bin
across simulations were recorded. Similarly, the 0.1, 0.5 and
0.9 quantiles of the sum of cell numbers across simulations
were recorded.
Data accessibility. Phenotypic ratios and estimated population sizes of
barcoded clones can be found in the electronic supplementary
material, table S1. The phenotypic ratios of single-cell clones can be
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the NCBI gene expression omnibus at GSE57872 [18]. Codes associ-
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